On October 14, 2026, the FDA announced the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development, led by its Rare Disease Innovation Hub, with …
On October 14, 2026, the FDA announced the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development, led by its Rare Disease Innovation Hub, with …
The FDA on October 14 expanded Anktiva (nogapendekin alfa inbakicept-pmln) to adults with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, as ImmunityBio works through a March warning letter over its promotion …
The FDA approved GSK and Ionis’s bepirovirsen for a narrow group of adults with chronic hepatitis B; 19% of treated trial patients still had the virus controlled, with hepatitis B …
Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven …
Two Medtronic cardiac devices had ANVISA registrations published on September 21, 2026, about 35 and 17 months after FDA approval, while BAGUERA C, Belotero and SELUTION SLR were registered in …
Bio-Techne shareholders have approved the $11.3 billion acquisition by Merck KGaA of Darmstadt, Germany, clearing a key procedural milestone as the deal moves toward a close expected by late 2026 …
Telix Pharmaceuticals agrees to acquire ITM Isotope Technologies Munich for up to $2.35 billion, securing isotope supply and adding ITM-11, a Phase 3 neuroendocrine tumour candidate that received an FDA …
The FDA approved belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma after prior immunotherapy, adding a second approved indication for belzutifan in 2026 and expanding Merck …
The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and …
The FDA has approved zilurgisertib (Atebrioz) for fibrodysplasia ossificans progressiva in patients aged 12 and older, making it the third approved FOP therapy and the second in five weeks.
You must be logged in to post a comment.